Another summer day, another Enhertu update.
The AstraZeneca-Daiichi Sankyo antibody-drug conjugate has successfully passed another trial, this time a Phase III trial testing the cancer drug against physician’s choice in patients with HER2-positive metastatic breast cancer.
The DESTINY-Breast02 study beat other treatments – trastuzumab/capecitabine or lapatinib/capecitabine – by improving progression-free survival and a secondary endpoint, overall survival.
Following a historic data drop at ASCO earlier this summer, Enhertu has had a winning streak, including two label expansions this month – low HER2 metastatic breast cancer and lung cancer. non-small cell metastatic with previously treated HER2 mutation.
Britain’s big pharma didn’t release any further details about the trial of around 600 patients, other than that no new safety issues emerged, consistent with previous late-stage trials of the drug.
“The rates and severity of interstitial lung disease (ILD) were consistent with those seen in other Enhertu metastatic breast cancer trials., with a low rate of observed grade 5 ILD events, as determined by an independent screening committee,” the company said in its statement.
“As this is the confirmatory trial for our current breast cancer indication in Europe and several other countries, we look forward to sharing these results with regulatory authorities to add to the body of evidence for Enhertu for the treatment of HER2-positive metastatic breast cancer,” Ken Takeshita, global head of R&D at Daiichi Sankyo, said in a statement.
The news comes just days after Daiichi Sankyo cleared a major litigation hurdle, with Seagen losing an arbitration dispute with the company over its ADC technology.